Lifecore Biomedical, Inc. LFCR Ratios & Valuation
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Liquidity | |||||
| Current ratio | 3.8×+0.9× | 2.8×+0.8× | 2.1×-0.3× | 2.4×+1.7× | |
| Quick ratio | 2.4×+0.6× | 1.8×+0.7× | 1×-0.3× | 1.3×+0.9× | |
| Cash ratio | 1×+0.7× | 0.3×+0.1× | 0.2×-0.3× | 0.5×+0.5× | |
| Leverage | |||||
| Debt-to-assets | 0.7×+0.6× | 0×-0.4× | 0.4×+0.1× | 0.4×0.0× | |
| Per Share | |||||
| Book value per share | -$0.76-2,076% | $0.04-87.6% | $0.31+319% | -$0.14-105% | |
| Valuation | |||||
| Market capitalization | $196.92M-35.4% | $259.18M+46.4% | $177.08M-28.7% | $248.34M-11.3% | |
| Enterprise value | $333.06M+8.3% | $262.04M-6.2% | $279.46M-14.0% | $325.06M-17.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Lifecore Biomedical, Inc.'s profit margins?
- Lifecore Biomedical, Inc. (LFCR) runs a 31.3% gross margin and a -14.5% operating margin, with a -30.0% net margin.
- Where do Lifecore Biomedical, Inc.'s ratios come from?
- Every ratio is computed from Lifecore Biomedical, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
